1. Inflammation/Immunology

Inflammation/Immunology

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160225
    ISD sodium 98.02%
    ISD sodium is an interferon-stimulatory DNA, a 45 bp non-CpG double-stranded oligonucleotide derived from the genome of Listeria monocytogenes. ISD sodium potently induces type I interferon production via the cGAS‑STING‑TBK1‑IRF3 pathway.
    ISD sodium
  • HY-U00434
    3BDO 890405-51-3 99.93%
    3BDO is a IFITM3 modulator and mTOR activator with antiviral and autophagy-inhibiting effects. 3BDO exhibits inhibitory activity against porcine coronaviruses. 3BDO increases the protein abundance of IFITM3, inhibits virus-cell membrane fusion, and blocks viral entry. 3BDO inhibits the entry of transmissible gastroenteritis virus, porcine epidemic diarrhea virus, and porcine respiratory coronavirus into host cells. 3BDO can be used for research on porcine coronavirus infection.
    3BDO
  • HY-108463
    A-967079 1170613-55-4 99.30%
    A-967079 is a selective TRPA1 receptor antagonist with IC50s of 67 nM and 289 nM at human and rat TRPA1 receptors, respectively, and has good penetration into the blood-brain barrier.
    A-967079
  • HY-P99020
    Fresolimumab 948564-73-6 99.51%
    Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease.
    Fresolimumab
  • HY-150741
    ODN 2216 332437-00-0 98.57%
    ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4+ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4+ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8+ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus.
    ODN 2216
  • HY-P99462
    Barzolvolimab 2438203-51-9
    Barzolvolimab is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria.
    Barzolvolimab
  • HY-112885B
    nor-NOHA monoacetate 2250019-93-1 99.94%
    nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism.
    nor-NOHA monoacetate
  • HY-12532
    Astemizole 68844-77-9 99.77%
    Astemizole (R 43512), a second-generation antihistamine agent to diminish allergic symptoms with a long duration of action, is a histamine H1-receptor antagonist, with an IC50 of 4 nM. Astemizole also shows potent hERG K+ channel blocking activity with an IC50 of 0.9 nM. Astemizole has antipruritic effects.
    Astemizole
  • HY-N0575
    Pinocembrin 480-39-7 99.68%
    Pinocembrin ((+)-Pinocoembrin) is a flavonoid found in propolis, acts as a competitive inhibitor of histidine decarboxylase, and is an effective anti-allergic agent, with antioxidant, antimicrobial and anti-inflammatory properties.
    Pinocembrin
  • HY-107383
    Tetrahydrobiopterin 17528-72-2 99.72%
    Tetrahydrobiopterin ((Rac)-Sapropterin) is a cofactor of the aromatic amino acid hydroxylases enzymes and also acts as an essential cofactor for all nitric oxide synthase (NOS) isoforms.
    Tetrahydrobiopterin
  • HY-W010155
    Tryptophol 526-55-6 ≥98.0%
    Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces apoptosis and cleavage of caspase-8. Tryptophol inhibits Cunninghamella blakesleeana biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy.
    Tryptophol
  • HY-125854
    Phosphatidylcholines, egg 97281-44-2 ≥99.0%
    Phosphatidylcholines, egg are a type of phosphatidylcholine that can be isolated and extracted from eggs, primarily present in egg yolks. As a major phospholipid component of cell membranes, Phosphatidylcholines, egg play a key role in providing nutrition and protection to the body. Phosphatidylcholines, egg can inhibit oxidative stress and neurotoxicity, exerting neuroprotective effects. Additionally, Phosphatidylcholines, egg can suppress the lymphatic absorption of cholesterol in the intestine and are also used in research on intestinal lipid absorption.
    Phosphatidylcholines, egg
  • HY-133129
    MS1943 2225938-17-8 98.92%
    MS1943 is an orally active selective HyT degrader of EZH2 that effectively reduces EZH2 levels in cells. MS1943 has anticancer activity and exhibits cytotoxic effects in a variety of TNBC cells while sparing normal cells. In addition, MS1943 maintains high potency (IC50=120 nM) in inhibiting EZH2 methyltransferase activity and is highly selective for EZH2. (Structure Note: RED, EZH2 ligand (HY-148458); Blue, Hyt (HY-W001578)).
    MS1943
  • HY-14302
    Salmeterol 89365-50-4 99.69%
    Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
    Salmeterol
  • HY-100113
    Buloxibutid 477775-14-7 98.94%
    Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis.
    Buloxibutid
  • HY-100432
    LOC14 877963-94-5 98.0%
    LOC14 is a potent Protein disulfide isomerase (PDI) inhibitor with EC50 and Kd values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding. LOC14 inhibits PDIA3 activity, decreases intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in lung epithelial cells.
    LOC14
  • HY-126675A
    AS2863619 2241300-51-4 98.02%
    AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene.
    AS2863619
  • HY-P99009
    Batoclimab 2187430-05-1 99.89%
    Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease.
    Batoclimab
  • HY-19344
    Lifitegrast 1025967-78-5 99.29%
    Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease.
    Lifitegrast
  • HY-B1028
    Pantethine 16816-67-4 ≥98.0%
    Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration.
    Pantethine
Cat. No. Product Name / Synonyms Application Reactivity